AAIC 2019

Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019

Without Significant Effects on Synaptic Function in Brain by Spinal Densitiy Evaluation at Effective Dose to Decrease Amyloid Beta Level…

5 years ago

Latest Data on Eisai’s Alzheimer’s Disease/ Dementia Pipeline to be Presented at AAIC 2019

Tokyo, July 11, 2019: Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including…

5 years ago